Your Patient Is Taking a Compounded GLP-1. Now What?

As demand for GLP-1 receptor agonists continues to outpace supply, many patients have turned to compounded medications obtained through telehealth companies, medical spas, wellness clinics, and compounding pharmacies. While these products may improve access for some individuals, they also introduce important clinical, regulatory, and medicolegal challenges. Providers increasingly encounter patients who have already started treatment before establishing care or without a traditional prescription pathway.

Understanding the clinical safety of compounded GLP-1 therapies has therefore become an essential part of diabetes and obesity management. Rather than dismissing or criticizing patients for their choices, clinicians should objectively evaluate potential risks, verify exactly what the patient is taking, and develop a safe, evidence-based treatment plan that preserves trust while strengthening the therapeutic relationship.

Table of Contents

• Why patients are turning to compounded GLP-1 therapies
• Understanding the safety concerns of compounded GLP-1 products
• How to evaluate patients taking compounded GLP-1 medications
• Documentation, counseling, and transitioning to FDA-approved therapy
• Frequently Asked Questions

Why Patients Are Turning to Compounded GLP-1 Therapies

Several factors have fueled the rapid growth of compounded GLP-1 therapies. National shortages of branded semaglutide and tirzepatide have made access difficult. Even when medications are available, insurance denials and high out-of-pocket costs often leave patients searching for alternatives.

Telehealth platforms have also expanded access by offering online consultations, home delivery, and subscription-based treatment models. Many patients believe these medications are equivalent to FDA-approved products because they produce similar weight loss or glycemic improvements.

However, patients frequently do not understand the differences between FDA-approved medications and compounded formulations. Some are unaware that compounded products are not reviewed by the FDA for safety, effectiveness, or manufacturing consistency before reaching the patient. Others may not know whether they are receiving semaglutide base, semaglutide sodium, semaglutide acetate, or another formulation entirely.

This knowledge gap creates an opportunity for clinicians to educate patients without damaging the therapeutic relationship.

Understanding the Safety Concerns of Compounded GLP-1 Therapies

The primary concern when evaluating compounded GLP-1 clinical safety is product quality, consistency, and manufacturing oversight. FDA-approved GLP-1 receptor agonists undergo extensive manufacturing controls, stability testing, and quality assurance. Compounded medications, while legally appropriate under certain circumstances, are produced under different regulatory standards.

Clinicians should consider several potential concerns during evaluation:

• Unknown active ingredient source
• Variable potency or concentration
• Differences in excipients
• Sterility concerns for injectable products
• Dosing inaccuracies
• Limited stability data
• Inconsistent patient instructions

The FDA has also warned healthcare professionals about compounded products made with salt forms of semaglutide that differ from the approved active ingredient. In addition, adverse events have been reported from dosing errors, particularly when patients measure multidose vials using insulin syringes instead of fixed-dose pen devices.

A thorough medication review should go beyond simply asking whether the patient is taking semaglutide or tirzepatide. Instead, clinicians should determine exactly which formulation the patient received, where it was compounded, how it is administered, whether dosing instructions are appropriate, and whether the patient understands how to use the medication safely.

How to Evaluate Patients Taking Compounded GLP-1 Medications

When a patient presents using a compounded GLP-1 product, the initial conversation should remain nonjudgmental. Many patients pursued these therapies after encountering significant barriers within the healthcare system. Approaching the discussion with curiosity rather than criticism encourages honest disclosure.

Begin by confirming:

• Product name
• Active ingredient
• Dose and concentration
• Source pharmacy or clinic
• Route of administration
• Duration of therapy
• Titration schedule
• Concurrent medications

Next, assess treatment response. Review weight change, glycemic control, gastrointestinal symptoms, hypoglycemia risk, hydration status, pancreatitis history, gallbladder symptoms, and medication adherence.

Medication reconciliation becomes especially important because patients often receive compounded products through providers outside their primary healthcare team. Electronic health records may not capture these medications unless clinicians specifically ask.

Whenever possible, request photographs of medication labels, packaging, prescription information, or pharmacy documentation. These details may help clarify product identity and support accurate documentation.

Laboratory monitoring should be guided by the patient’s clinical presentation and may include A1C, renal function, liver enzymes when indicated, electrolyte assessment for patients with significant gastrointestinal symptoms, and additional testing based on comorbid conditions.

Documentation, Counseling, and Transitioning to FDA-Approved Therapy

Many patients worry their physician will immediately tell them to stop therapy. While abrupt discontinuation may be appropriate in certain situations, a collaborative discussion often produces better outcomes.

Explain that your goal is not to criticize their decision but to ensure they receive safe and effective treatment. Patients generally respond positively when providers acknowledge the financial and access barriers that influenced their choices.

Discuss the differences between compounded medications and FDA-approved products using clear, factual language. Focus on manufacturing oversight, quality assurance, dosing consistency, and available clinical evidence rather than assigning blame.

If concerns exist regarding product quality or safety, explain those concerns transparently while offering practical alternatives whenever possible.

For patients who qualify, consider transitioning to an FDA-approved GLP-1 receptor agonist when supply, insurance coverage, and affordability permit. If immediate transition is not feasible, establish an appropriate monitoring plan while continuing shared decision-making.

Resources from the U.S. Food and Drug Administration can support patient education regarding compounded medications. Providers can also follow evolving recommendations from organizations such as the American Diabetes Association.

Thorough documentation is an important part of safely managing patients who use compounded GLP-1 medications. The medical record should clearly identify that the patient reports using a compounded medication rather than an FDA-approved product when appropriate.

Documentation should include the reported product source, patient-reported dose, counseling provided, risks discussed, shared decision-making, monitoring plan, and follow-up recommendations. Avoid assumptions regarding product quality if specific evidence is unavailable. Instead, document objective findings, patient statements, and your clinical assessment.

Comprehensive documentation supports continuity of care while demonstrating thoughtful clinical decision-making should questions arise later.

Conclusion

Compounded GLP-1 therapies are likely to remain part of clinical practice as long as shortages, affordability challenges, and growing patient demand continue. Rather than viewing these patients as difficult or noncompliant, clinicians should recognize the systemic factors that influenced their decisions.

Focusing on the safe use of compounded GLP-1 therapies allows providers to identify potential risks, educate patients using evidence-based information, and develop individualized treatment plans that prioritize both safety and trust. By combining careful medication assessment with empathetic communication and thorough documentation, clinicians can help patients transition toward the safest and most appropriate therapy available.

Frequently Asked Questions

Are compounded GLP-1 medications FDA approved?

No. Compounded medications are not FDA approved, although compounding may be permitted under specific legal circumstances.

Should patients immediately stop taking compounded GLP-1 products?

Not necessarily. Decisions should be individualized based on product source, patient condition, clinical response, and safety assessment.

What information should clinicians verify first?

Confirm the exact medication, concentration, dosing schedule, source pharmacy, administration technique, and duration of use.

Can compounded GLP-1 medications affect medication reconciliation?

Yes. Because these medications are often prescribed outside traditional healthcare systems, they may not appear in electronic health records unless specifically documented.

What is the biggest concern regarding compounded GLP-1 clinical safety?

The primary concerns include manufacturing consistency, dosing accuracy, product quality, sterility, and limited regulatory oversight compared with FDA-approved medications.

Disclaimer: This content is intended for educational purposes only and should not replace independent clinical judgment or current prescribing information. Healthcare professionals should consult applicable FDA guidance, professional society recommendations, and institutional policies when managing individual patients.